Hypermarcas (OTCMKTS:HYPMY) Trading Down 5.7% – What’s Next?

Hypermarcas (OTCMKTS:HYPMY – Get Free Report)’s stock price fell 5.7% during mid-day trading on Monday . The company traded as low as $3.96 and last traded at $3.96. 59,253 shares were traded during trading, an increase of 140% from the average session volume of 24,652 shares. The stock had previously closed at $4.20.

Analysts Set New Price Targets

Separately, Zacks Research upgraded Hypermarcas to a “hold” rating in a research report on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, Hypermarcas currently has a consensus rating of “Buy”.

Get Hypermarcas alerts:

Get Our Latest Research Report on HYPMY

Hypermarcas Stock Down 5.7%

The stock has a market cap of $2.79 billion, a PE ratio of 8.25 and a beta of 0.70. The company has a current ratio of 1.27, a quick ratio of 0.84 and a debt-to-equity ratio of 0.61. The business has a 50-day moving average price of $4.53 and a 200-day moving average price of $4.49.

Hypermarcas (OTCMKTS:HYPMY – Get Free Report) last announced its earnings results on Wednesday, April 29th. The company reported $0.10 earnings per share (EPS) for the quarter. Hypermarcas had a return on equity of 14.08% and a net margin of 19.41%.The firm had revenue of $383.13 million for the quarter. As a group, analysts forecast that Hypermarcas will post 0.53 earnings per share for the current year.

About Hypermarcas

(Get Free Report)

Hypermarcas SA is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors.

Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products.

Recommended Stories

• Five stocks we like better than Hypermarcas
• 3 Stocks With Fresh Catalysts to Watch Before the July 4
• Amprius Insiders Are Selling: Should Investors Be Worried?
• A Weaker Dollar Could Put These 3 Industrial Stocks Back in Focus
• A Market Rotation Toward Quality Will Benefit These 3 ETFs

Receive News & Ratings for Hypermarcas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypermarcas and related companies with MarketBeat.com's FREE daily email newsletter.